Ampio shares are routed (again) as its PhIII do-over for osteoarthritis flops
Last April little Ampio Pharmaceuticals $AMPE struggled to put the best face on the Phase III failure of its osteoarthritis drug Ampion. The dread placebo effect scuttled the study, execs protested, as its stock was crushed in the instant rout.
By last fall, though, the Englewood, CO-based biotech came back with a new Phase III, significantly de-risked, they said, based on prior results and a special protocol assessment with the FDA that put success within their grasp.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
